title: [Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma].
abstract: OBJECTIVE
  To evaluate the efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma.
  
  
  METHODS
  Perspective study.Eleven patients (11 eyes) with the diagnosis of refractory retinoblastoma were enrolled in Department of Ophthalmology of Peking University People's Hospital from June 2013 to March 2014. They underwent intravitreal carboplatin plus bevacizumab every 4 weeks, an average of 4.5 times of treatment.Observe for 3 months after the last treatment. Aqueous humor was taken for cytological and VEGF detection and retinal funds were taken photos for observation.Statistical analyses between experimental group and control group and before and after intravitreal injection within experimental group were performed with independent samples t test.
  
  
  RESULTS
  Tumor in vitreous cavity reduced significantly in seven patients, however, poor control in four cases, and three of them were recurrent after first-line treatment. Cytology detection for aqueous humor showed no tumor cells in all of them. Aqueous VEGF of patients with retinoblastoma (60.65 ± 6.20) was significantly higher than the control group (21.98 ± 6.91). The difference was statistically significant (t = 13.80, P < 0.01). And the aqueous VEGF content decreased significantly after treatment (t = 2.12, P < 0.05).
  
  
  CONCLUSIONS
  Intravitreal carboplatin plus bevacizumab, is a relatively safe, effective treatment for refractory retinoblastoma, however, ineffective for recurrent tumor.
authors.affiliation: Department of Ophthalmology People Eye Institute, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors.forename: Xianru
authors.initials: X
authors.lastname: Hou
authors.affiliation: Department of Ophthalmology People Eye Institute, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Cheng
authors.affiliation: Department of Ophthalmology People Eye Institute, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Ophthalmology People Eye Institute, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China. Email:jianhongliang@hotmail.com.
authors.forename: Jianhong
authors.initials: J
authors.lastname: Liang
authors.affiliation: Department of Ophthalmology People Eye Institute, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors.forename: Xiaoxin
authors.initials: X
authors.lastname: Li
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000737:chemistry / Q000166:cytology; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D009364:Neoplasm Recurrence, Local; D019572:Retinal Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D012175:Retinoblastoma / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis; D014822:Vitreous Body
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D016190:Carboplatin